Yemaachi

Businessfiled

Yemaachi operates in Biotech, based in Africa. Ghanaian cancer research and diagnostics company Yemaachi Biotech has closed a US$3 million seed round to advance its mission of diversifying precision oncology globally.

Sub-sector tags: biotech, medical-devices, pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Yemaachi has raised $3.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.0M on 2022-03-25.

Most recent recorded round closed around 2022-03-25.

Valuation (modeled)modeled

Provath models Yemaachi at approximately $51M (range $2.2M–$251M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 3.87× the median modeled value of Seed Biotech companies in 2022–2024 (6 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 4.3 yr ago; this sector typically re-raises about every 11 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 76% of Biotech peers (233 compared).

Modeled value ranks above 83% of those peers.

Closest niche peers: INVO Bioscience, Inc., General Genomics Inc., MET Biotechnology Inc., J3 Bioscience, Inc., Psycheceutical Bioscience, Inc..

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.